Buchumschlag

No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group

Chronic myeloid leukaemia, imatinib, hydroxyurea/imatinib, outcome, phase I, phase II

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Lange, Thoralf (VerfasserIn) , Niederwieser, Christian (VerfasserIn) , Gil, Arthur (VerfasserIn) , Krahl, Rainer (VerfasserIn) , Grünhagen, Ulrich von (VerfasserIn) , Al-Ali, Haifa Kathrin (VerfasserIn) , Jentsch-Ullrich, Kathleen (VerfasserIn) , Spohn, Claudia (VerfasserIn) , Lakner, Volker (VerfasserIn) , Assmann, Michael (VerfasserIn) , Junghanss, Christian (VerfasserIn) , Cross, Michael (VerfasserIn) , Hehlmann, Rüdiger (VerfasserIn) , Deininger, Michael (VerfasserIn) , Pfirrmann, Markus (VerfasserIn) , Niederwieser, Dietger (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2020
In: Leukemia and lymphoma
Year: 2020, Jahrgang: 61, Heft: 12, Pages: 2821-2830
ISSN:1029-2403
DOI:10.1080/10428194.2020.1786556
Online-Zugang:Resolving-System, lizenzpflichtig: https://doi.org/10.1080/10428194.2020.1786556
Volltext
Verfasserangaben:Thoralf Lange, Christian Niederwieser, Arthur Gil, Rainer Krahl, Ulrich von Grünhagen, Haifa Kathrin Al-Ali, Kathleen Jentsch-Ullrich, Claudia Spohn, Volker Lakner, Michael Assmann, Christian Junghanss, Michael Cross, Rüdiger Hehlmann, Michael Deininger, Markus Pfirrmann, Dietger Niederwieser

MARC

LEADER 00000caa a2200000 c 4500
001 1755367066
003 DE-627
005 20220819170817.0
007 cr uuu---uuuuu
008 210419s2020 xx |||||o 00| ||eng c
024 7 |a 10.1080/10428194.2020.1786556  |2 doi 
035 |a (DE-627)1755367066 
035 |a (DE-599)KXP1755367066 
035 |a (OCoLC)1341404939 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Lange, Thoralf  |d 1970-  |e VerfasserIn  |0 (DE-588)120204029  |0 (DE-627)08051975X  |0 (DE-576)17837508X  |4 aut 
245 1 0 |a No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy  |b a study of the East German Study Group (OSHO) and the German CML study group  |c Thoralf Lange, Christian Niederwieser, Arthur Gil, Rainer Krahl, Ulrich von Grünhagen, Haifa Kathrin Al-Ali, Kathleen Jentsch-Ullrich, Claudia Spohn, Volker Lakner, Michael Assmann, Christian Junghanss, Michael Cross, Rüdiger Hehlmann, Michael Deininger, Markus Pfirrmann, Dietger Niederwieser 
264 1 |c 2020 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Chronic myeloid leukaemia, imatinib, hydroxyurea/imatinib, outcome, phase I, phase II 
700 1 |a Niederwieser, Christian  |d 1982-  |e VerfasserIn  |0 (DE-588)1121707556  |0 (DE-627)874917549  |0 (DE-576)48096761X  |4 aut 
700 1 |a Gil, Arthur  |e VerfasserIn  |4 aut 
700 1 |a Krahl, Rainer  |e VerfasserIn  |4 aut 
700 1 |a Grünhagen, Ulrich von  |e VerfasserIn  |4 aut 
700 1 |a Al-Ali, Haifa Kathrin  |d 1963-  |e VerfasserIn  |0 (DE-588)1033091529  |0 (DE-627)740787667  |0 (DE-576)380735504  |4 aut 
700 1 |a Jentsch-Ullrich, Kathleen  |e VerfasserIn  |0 (DE-627)1729154700  |4 aut 
700 1 |a Spohn, Claudia  |e VerfasserIn  |4 aut 
700 1 |a Lakner, Volker  |e VerfasserIn  |4 aut 
700 1 |a Assmann, Michael  |e VerfasserIn  |4 aut 
700 1 |a Junghanss, Christian  |e VerfasserIn  |4 aut 
700 1 |a Cross, Michael  |e VerfasserIn  |4 aut 
700 1 |a Hehlmann, Rüdiger  |d 1941-  |e VerfasserIn  |0 (DE-588)1037003489  |0 (DE-627)751737879  |0 (DE-576)390939463  |4 aut 
700 1 |a Deininger, Michael  |e VerfasserIn  |4 aut 
700 1 |a Pfirrmann, Markus  |d 1967-  |e VerfasserIn  |0 (DE-588)133124932  |0 (DE-627)534963617  |0 (DE-576)299639835  |4 aut 
700 1 |a Niederwieser, Dietger  |d 1952-  |e VerfasserIn  |0 (DE-588)1073549313  |0 (DE-627)829149120  |0 (DE-576)435151215  |4 aut 
773 0 8 |i Enthalten in  |t Leukemia and lymphoma  |d London [u.a.] : Taylor & Francis Group, 1989  |g 61(2020), 12, Seite 2821-2830  |h Online-Ressource  |w (DE-627)324746237  |w (DE-600)2030637-4  |w (DE-576)099718170  |x 1029-2403  |7 nnas  |a No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy a study of the East German Study Group (OSHO) and the German CML study group 
773 1 8 |g volume:61  |g year:2020  |g number:12  |g pages:2821-2830  |g extent:10  |a No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy a study of the East German Study Group (OSHO) and the German CML study group 
856 4 0 |u https://doi.org/10.1080/10428194.2020.1786556  |x Resolving-System  |z lizenzpflichtig 
951 |a AR 
992 |a 20220509 
993 |a Article 
994 |a 2020 
998 |g 1037003489  |a Hehlmann, Rüdiger  |m 1037003489:Hehlmann, Rüdiger  |d 60000  |e 60000PH1037003489  |k 0/60000/  |p 13 
999 |a KXP-PPN1755367066  |e 413034157X 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"given":"Thoralf","display":"Lange, Thoralf","role":"aut","family":"Lange"},{"role":"aut","family":"Niederwieser","display":"Niederwieser, Christian","given":"Christian"},{"role":"aut","family":"Gil","display":"Gil, Arthur","given":"Arthur"},{"role":"aut","family":"Krahl","display":"Krahl, Rainer","given":"Rainer"},{"display":"Grünhagen, Ulrich von","given":"Ulrich von","role":"aut","family":"Grünhagen"},{"given":"Haifa Kathrin","display":"Al-Ali, Haifa Kathrin","role":"aut","family":"Al-Ali"},{"display":"Jentsch-Ullrich, Kathleen","given":"Kathleen","family":"Jentsch-Ullrich","role":"aut"},{"given":"Claudia","display":"Spohn, Claudia","role":"aut","family":"Spohn"},{"family":"Lakner","role":"aut","given":"Volker","display":"Lakner, Volker"},{"family":"Assmann","role":"aut","display":"Assmann, Michael","given":"Michael"},{"role":"aut","family":"Junghanss","display":"Junghanss, Christian","given":"Christian"},{"role":"aut","family":"Cross","given":"Michael","display":"Cross, Michael"},{"role":"aut","family":"Hehlmann","given":"Rüdiger","display":"Hehlmann, Rüdiger"},{"given":"Michael","display":"Deininger, Michael","family":"Deininger","role":"aut"},{"family":"Pfirrmann","role":"aut","given":"Markus","display":"Pfirrmann, Markus"},{"role":"aut","family":"Niederwieser","given":"Dietger","display":"Niederwieser, Dietger"}],"recId":"1755367066","name":{"displayForm":["Thoralf Lange, Christian Niederwieser, Arthur Gil, Rainer Krahl, Ulrich von Grünhagen, Haifa Kathrin Al-Ali, Kathleen Jentsch-Ullrich, Claudia Spohn, Volker Lakner, Michael Assmann, Christian Junghanss, Michael Cross, Rüdiger Hehlmann, Michael Deininger, Markus Pfirrmann, Dietger Niederwieser"]},"language":["eng"],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"2020"}],"relHost":[{"pubHistory":["1.1989/90 -"],"note":["Gesehen am 08.09.15"],"part":{"text":"61(2020), 12, Seite 2821-2830","issue":"12","pages":"2821-2830","extent":"10","volume":"61","year":"2020"},"language":["eng"],"disp":"No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy a study of the East German Study Group (OSHO) and the German CML study groupLeukemia and lymphoma","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"324746237","origin":[{"dateIssuedDisp":"1989-","publisher":"Taylor & Francis Group ; Informa Healthcare","publisherPlace":"London [u.a.] ; London [u.a.]","dateIssuedKey":"1989"}],"id":{"eki":["324746237"],"issn":["1029-2403"],"zdb":["2030637-4"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Leukemia and lymphoma","title_sort":"Leukemia and lymphoma"}]}],"id":{"doi":["10.1080/10428194.2020.1786556"],"eki":["1755367066"]},"physDesc":[{"extent":"10 S."}],"title":[{"subtitle":"a study of the East German Study Group (OSHO) and the German CML study group","title":"No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy","title_sort":"No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy"}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} 
SRT |a LANGETHORANOADVANTAG2020 

Ähnliche Einträge